TetraLogic Pharmaceuticals (TLOG) is Initiated by ROTH Capital to Buy according to the research report released to the investors. The brokerage firm has set the Price Target of the shares at $5. The shares recommendation by the Brokerage Firm was released on Dec-31-2015.
The company shares have dropped 68.13% in the past 52 Weeks. On January 13, 2015 The shares registered one year high of $6.25 and one year low was seen on August 24, 2015 at $0.72. The 50-day moving average is $1.66 and the 200 day moving average is recorded at $2.12. S&P 500 has rallied 1.33% during the last 52-weeks.
Shares of TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) appreciated by 5.07% during the past week but lost 27.14% on a 4-week basis. The shares have outperformed the S&P 500 by 2.24% in the past week but underperformed the index by 26.11% in the last 4 weeks.
TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) : On Thursday heightened volatility was witnessed in TetraLogic Pharmaceuticals Corporation (NASDAQ:TLOG) which led to swings in the share price. The shares opened for trading at $1.42 and hit $1.62 on the upside , eventually ending the session at $1.45, with a gain of 0.69% or 0.01 points. The heightened volatility saw the trading volume jump to 500,176 shares. The 52-week high of the share price is $6.25 and the company has a market cap of $36 million. The 52-week low of the share price is at $0.72 .
On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Tetralogic Pharmaceuticals Corp, Pecora Andrew L, had purchased 50,000 shares in a transaction dated on July 10, 2015. The transaction was executed at $2.66 per share with total amount equaling $133,000.
TetraLogic Pharmaceuticals Corporation (TetraLogic) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing novel small molecule therapeutics that mimic Second Mitochondrial Activator of Caspases (SMAC)-mimetics, and are designed to cause or enable abnormal cells that are resistant to the body’s immune system to self-destruct. Birinapant, its clinical-stage product candidate, is being tested in Phase I and Phase II oncology clinical trials for multiple solid tumors and hematological malignancies. The Company’s clinical trials of birinapant have enrolled over 275 subjects. In April 2014,Tetralogic Pharmaceuticals Corp acquired the entire share capital of Shape Pharmaceutical Inc.